23 results
Thumbnail

D2.182 - Low-dose oral food challenge (OFC) in a pediatric day-care hospital: a pre-immunotherapy approach for managing nut-allergies in children

Thumbnail

D2.183 - Assessment of Incidence and Onset of Eosinophilic Esophagitis during the clinical development of Peanut (Arachis hypogaea) Allergen Powder-dried non-fat protein for oral immunotherapy

Thumbnail

D2.184 - Trends in aeroallergen immunotherapy prescription

Thumbnail

D2.185 - Ultrarush honeybee venom immunotherapy in patients with monoclonal mast cell activation syndrome: two case reports

Thumbnail

D2.186 - Toxicity Assessment of Repeated Doses of Apis mellifera Venom for Immunotherapy

Thumbnail

D2.187 - Can the Conjunctival Allergen Provocation Test Improve Long-Term Adherence to Subcutaneous Allergen-Specific Immunotherapy?

Thumbnail

D2.188 - Low allergenicity of food allergen by Galactomannan Conjugation and immunotherapeutic efficacy of peanut-galactomannan conjugate in a mouse model of peanut allergy

Thumbnail

D2.189 - Eosinophilic Esophagitis Induced by Sublingual Immunotherapy (SLIT): A Rare but Emerging Side Effect

Thumbnail

D2.190 - Unmasking Autoimmunity: A Case of Thyroiditis Emerging After Allergy Immunotherapy

Thumbnail

D2.191 - Autoimmune Disease Unmasked by Allergic Immunotherapy: A Case of Systemic Lupus Erythematosus (SLE) After SCIT

Thumbnail

D2.192 - IgE-Mediated Immunotherapy-Induced Eosinophilic Granulomatosis with Polyangiitis (EGPA)

Thumbnail

D2.193 - Oral Induction of Tolerance to Cow's Milk Protein Allergy in Omani Children: A Retrospective Analysis

Thumbnail

D3.419 - Prevalence of physical urticaria hives in patients with systemic mastocytosis and their relation to disease course – preliminary data

Thumbnail

D3.411 - Targeting MRGPRX2 for the Treatment of Mast Cell-Driven Diseases

Thumbnail

D3.412 - MRGPRX2 Specific Activation Signature is Enriched in Atopic Dermatitis Lesions and Wheals from Chronic Spontaneous Urticaria Compared to Adjacent Healthy Skin

Thumbnail

D3.413 - Development of the Mastocytosis Symptom Severity Daily Diary (MS2D2) for Non-Advanced Systemic Mastocytosis (NonAdvSM) Patients and Establishing Content Validity

Thumbnail

D3.414 - The Phase 2/3 Study of Elenestinib, a Highly Potent and Selective Tyrosine Kinase Inhibitor, in Patients With Indolent Systemic Mastocytosis

Thumbnail

D3.415 - Clinical manifestations of Hereditary alpha-tryptasemia (HaT) in Patients with Mast Cell Activation Syndromes

Thumbnail

D3.416 - Hereditary Alpha-Tryptasemia: A Case Series

Thumbnail

D3.417 - "Comprehensive Allergological Evaluation and Management of Severe Anaphylaxis to Vespid Venoms: A Case Study"